20:05 , Jan 12, 2017 |  BC Innovations  |  Emerging Company Profile

Looking beyond VEGF

SemaThera Inc. launched this week to develop a recombinant SEMA3A trap to treat vascular pathologies in the large fraction of diabetic macular edema (DME) patients who don’t respond to marketed anti- VEGF therapies. Semaphorins are...
07:00 , May 13, 2013 |  BC Week In Review  |  Financial News

InflammatoRx completes venture financing

InflammatoRx Inc. , Quebec City, Quebec   Business: Inflammation   Date completed: 5/7/13   Type: Venture financing   Raised: Not disclosed   Investor: AmorChem Venture Fund  ...